Literature DB >> 15000423

Optimization of individual and population designs using Splus.

Sylvie Retout1, France Mentré.   

Abstract

We address the problem of design optimization for individual and population pharmacokinetic studies. We develop Splus generic functions for pharmacokinetic design optimization: IFIM, a function for individual design optimization similar to the ADAPT II software, and PFIM_OPT, a function for population design optimization which is an extension of the Splus function PFIM for population design evaluation. Both evaluate and optimise designs using the Simplex algorithm. IFIM optimizes the sampling times in continuous intervals of times; PFIM_OPT optimizes either, for a given group structure of the population design, only the sampling times taken in some given continuous intervals or, both the sampling times and the group structure, performing then statistical optimization. A combined variance error model can be supplied with the possibility to include parameters of the error model as parameters to be estimated. The performance of the optimization with the Simplex algorithm is demonstrated with two pharmacokinetic examples: by comparison of the optimized designs to those of the ADAPT II software for IFIM, and to those obtained using a grid search or the Fedorov-Wynn algorithm for PFIM_OPT. The influence of the variance error model on design optimization was investigated. For a given total number of samples, different group structures of a population design are compared, showing their influence on the population design efficiency. The functions IFIM and PFIM_OPT offer new efficient solutions for the increasingly important task of optimization of individual or population pharmacokinetic designs.

Mesh:

Year:  2003        PMID: 15000423     DOI: 10.1023/b:jopa.0000013000.59346.9a

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  17 in total

1.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.

Authors:  S Retout; S Duffull; F Mentré
Journal:  Comput Methods Programs Biomed       Date:  2001-05       Impact factor: 5.428

Review 2.  Simulation of clinical trials.

Authors:  N H Holford; H C Kimko; J P Monteleone; C C Peck
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

3.  Population modelling in drug development.

Authors:  L Sheiner; J Wakefield
Journal:  Stat Methods Med Res       Date:  1999-09       Impact factor: 3.021

4.  Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.

Authors:  Y Merlé; M Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-08       Impact factor: 2.745

5.  Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics.

Authors:  Sylvie Retout; France Mentré
Journal:  J Biopharm Stat       Date:  2003-05       Impact factor: 1.051

6.  An evaluation of population D-optimal designs via pharmacokinetic simulations.

Authors:  Andrew C Hooker; Marco Foracchia; Michael G Dodds; Paolo Vicini
Journal:  Ann Biomed Eng       Date:  2003-01       Impact factor: 3.934

7.  Experimental design and efficient parameter estimation in population pharmacokinetics.

Authors:  M K al-Banna; A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

8.  Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments.

Authors:  D Z D'Argenio
Journal:  Math Biosci       Date:  1990-04       Impact factor: 2.144

9.  Comparison of some practical sampling strategies for population pharmacokinetic studies.

Authors:  E N Jonsson; J R Wade; M O Karlsson
Journal:  J Pharmacokinet Biopharm       Date:  1996-04

10.  Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.

Authors:  M Tod; J M Rocchisani
Journal:  J Pharmacokinet Biopharm       Date:  1997-08
View more
  25 in total

1.  Sample size computations for PK/PD population models.

Authors:  Dongwoo Kang; Janice B Schwartz; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

Review 2.  On some "disadvantages" of the population approach.

Authors:  Jerry R Nedelman
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 3.  A pragmatic approach to the design of population pharmacokinetic studies.

Authors:  Amit Roy; Ene I Ette
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 4.  Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.

Authors:  Jenny Y Chien; Stuart Friedrich; Michael A Heathman; Dinesh P de Alwis; Vikram Sinha
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

Review 5.  Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.

Authors:  C Dartois; K Brendel; E Comets; C M Laffont; C Laveille; B Tranchand; F Mentré; A Lemenuel-Diot; P Girard
Journal:  Br J Clin Pharmacol       Date:  2007-08-15       Impact factor: 4.335

6.  Commentary on Dartois et al.--model building in population PK-PD analyses. A 2002-2004 literature survey.

Authors:  Goonaseelan Pillai; Jean-Louis Steimer
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

7.  Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.

Authors:  Julie Bertrand; Emmanuelle Comets; France Mentre
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

8.  Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics.

Authors:  François Pierre Combes; Sylvie Retout; Nicolas Frey; France Mentré
Journal:  Pharm Res       Date:  2013-06-07       Impact factor: 4.200

9.  Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4.

Authors:  Marion Bouillon-Pichault; Vincent Jullien; Caroline Bazzoli; Gérard Pons; Michel Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-04       Impact factor: 2.745

10.  Utilization of optimal study design for maternal and fetal sheep propofol pharmacokinetics study: a preliminary study.

Authors:  Catherine M T Sherwin; Pornswan Ngamprasertwong; Senthilkumar Sadhasivam; Alexander A Vinks
Journal:  Curr Clin Pharmacol       Date:  2014-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.